Renaissance Capital logo

MRVI News

These IPOs have outperformed during the biggest sell-off in over a decade

SWCH

The US IPO Index has plummeted 51% year-to-date, in the IPO market’s sharpest sell-off since at least the 2008 Global Financial Crisis. Of the 397 traditional IPOs in 2021, only 12% are trading above issue. Rampant speculation and near-zero interest rates helped fuel sky-high valuations last year, but with inflation at a 40-year high, the US Fed has begun to rapidly tighten...read more

US IPO Week Ahead: The IPO market makes a holiday WISH in a 6 IPO week

WISH

Updated Monday, 12/14. Six IPOs and five SPACs are scheduled to raise $2.8 billion in the week ahead as the IPO market starts to slow down before the holidays. Bargain e-commerce platform Wish (WISH) plans to raise $1.1 billion at a $16.4 billion market cap. The company provides an e-commerce platform that connects primarily China-based...read more

US IPO Weekly Recap: Breast cancer biotech pops 158% in a 6 IPO week

OLMA

In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals (OLMA), which soared 158% on its first day. New filings continued to pour in, priming the IPO pipeline for an active end to 2020. The week’s top performer, Phase 1 biotech ...read more

Genetic products supplier Maravai LifeSciences prices upsized IPO at $27 high end

MRVI

Maravai LifeSciences, which provides genetic products and testing services for drug development and research, raised $1.6 billion by offering 60 million shares at $27, the high end of the $24 to $27 range. As a supplier of oligonucleotides and products used to stabilize mRNA, Maravai stands to benefit from mRNA in vaccines and cell therapies, which include some promising...read more